Quoin Pharmaceuticals Advances in Netherton Syndrome Treatment Study
Quoin Pharmaceuticals Ltd is conducting a clinical study on QRX003 lotion for treating Netherton syndrome, a genetic skin disorder. The study evaluates the lotion's effectiveness and safety over 12 weeks, focusing on symptom improvement. It began on April 7, 2025, and is currently recruiting participants. Positive results could enhance Quoin's market position and influence its stock performance, given the niche market for Netherton syndrome treatments.
Quoin Pharmaceuticals Ltd is conducting a clinical study titled ‘A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndrome.’ The study aims to evaluate the effectiveness and safety of QRX003, a topical lotion, in treating Netherton syndrome, a genetic skin disorder. The primary objectives are to assess the improvement in clinical symptoms and identify any medical issues arising from the treatment.
The intervention being tested is QRX003, a 4% topical lotion applied twice daily. It is designed to alleviate symptoms of Netherton syndrome by acting as a serine protease inhibitor.
This open-label study follows a single-group intervention model without masking. Its primary purpose is treatment, focusing on the direct application of QRX003 to affected areas, excluding the scalp, over a 12-week period.
The study began on April 7, 2025, with the latest update submitted on July 16, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status.
The study’s progress could influence Quoin Pharmaceuticals’ stock performance, as successful results might boost investor confidence. Given the niche market for Netherton syndrome treatments, positive outcomes could position Quoin as a leader in this area, potentially impacting competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.
